Key result
Expanded polytetrafluoroethylene (ePTFE) handmade valves for pulmonary valve replacement demonstrated 90.2% freedom from reintervention at 5 years and 96.7% survival at 3 years.
Why the study?
Unmet needs remain for right ventricular outflow reconstruction to resolve pulmonary regurgitation after corrective surgery for congenital heart diseases, prompting review of the evolution of handmade ePTFE valves.
Do ePTFE handmade valves provide reliable clinical outcomes compared to allograft or xenograft options for pulmonary valve replacement in congenital heart disease?
Do ePTFE handmade valves provide reliable clinical outcomes compared to allograft or xenograft options for pulmonary valve replacement in congenital heart disease?
Answers are grounded in this paper and cite their sources.
Handmade ePTFE valves demonstrate non-inferior clinical outcomes compared to allografts or xenografts for pulmonary valve replacement, with excellent mid-term survival and freedom from reintervention.
OBJECTIVES: Many surgeons develop unique techniques for unmet needs for right ventricular outflow reconstruction to resolve pulmonary regurgitation after corrective surgery for congenital heart diseases. Expanded polytetrafluoroethylene (ePTFE) stands out as a reliable synthetic material, and clinical results with handmade ePTFE valves have been promising. This review focuses on the historical evolution of the use of ePTFE in pulmonary valve replacement and in the techniques for pioneering the translation of the handmade ePTFE trileaflet design for the transcatheter approach. METHODS: We searched for and reviewed publications from 1990 to 2020 in the Pubmed database. Nineteen clinical studies from 2005 to 2019 that focused on ePTFE-based valves were summarized. The evolution of the ePTFE-based valve over 3 decades and recent relevant in vitro studies were investigated. RESULTS: The average freedom from reintervention or surgery in the recorded ePTFE-based valve population was 90.2% at 5 years, and the survival rate was 96.7% at 3 years. CONCLUSIONS: Non-inferior clinical results of this ePTFE handmade valve were revealed compared to allograft or xenograft options for pulmonary valve replacement. Future investigations on transferring ePTFE trileaflet design to transcatheter devices should be considered.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2020) conducted a review in Pulmonary regurgitation after corrective surgery for congenital heart diseases. Expanded polytetrafluoroethylene (ePTFE) handmade valves vs. Allograft or xenograft options was evaluated on Freedom from reintervention or surgery. Expanded polytetrafluoroethylene (ePTFE) handmade valves for pulmonary valve replacement demonstrated 90.2% freedom from reintervention at 5 years and 96.7% survival at 3 years.
Synapse has enriched 10 related papers. Consider them for comparative context: